CAREPNEUMO (223111)

  https://cordis.europa.eu/project/id/223111

  FP7 (2007-2013)

  Combating Antibiotics Resistant Pneumococci by Novel Strategies Based on in vivo and in vitro Host – Pathogen Interactions

  Host-pathogen interactions in infections by Streptococcus pneumoniae (HEALTH-2007-2.3.1-2)

  mortality  ·  epidemiology  ·  vaccines  ·  antibiotics  ·  antibiotic resistance

  2009-03-01 Start Date (YY-MM-DD)

  2012-02-29 End Date (YY-MM-DD)

  € 3,969,999 Total Cost


  Description

The diseases caused by Streptococcus pneumoniae are a major public health problem all over the world. Children, elderly people and immuno-compromised individuals are the high-risk targets for pneumococcal diseases. In spite of the availability of a large number of antibiotics the mortality and morbidity due to S. pneumoniae infections remain very high. There are two reasons for this: Firstly, the increasing antibiotic resistance among pneumococcal strains, and secondly, a current vaccine, though effective for certain serotypes, leads to serotype replacement. For the development of combat strategies it is essential to identify new intervention strategies, for which an understanding of host-pathogen interaction is a prerequisite. This proposal would apply a multi-disciplinary approach that includes epidemiology, host-pathogen interactions, infection models and intervention strategies to combat antibiotic resistant S. pneumoniae. The consortium brings together 12 research organizations and 1 SME with expertise in the above-mentioned areas. The major objectives of this consortium will be 1. monitoring of prevalent S. pneumoniae serotypes and their resistance profiles in different countries, 2. analysis of host-pathogen interactions and identification of potential therapeutic targets and vaccine candidates, 3. providing a basis for the development of improved vaccine and intervention strategies. This joint international effort would contribute towards novel control strategies, especially of antibiotic resistant S. pneumoniae strains.


  Complicit Organisations

1 Israeli organisation participates in CAREPNEUMO.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
Germany UNIVERSITAETSKLINIKUM AACHEN (999897632) DE813100566 participant HES € 0 € 199,980 € 0
Greece ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON (999643007) EL090145420 participant HES € 0 € 155,100 € 0
India POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH (997203748) nan participant REC € 0 € 72,300 € 0
Poland NARODOWY INSTYTUT LEKOW (998545452) PL5213212384 participant REC € 0 € 138,600 € 0
Israel Protea Vaccine Technologies Ltd. (997438100) nan participant PRC € 0 € 152,400 € 0
Spain AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (999991722) ESQ2818002D participant REC € 0 € 344,115 € 0
Argentina HOSPITAL DE PEDIATRIA SAMIC PROF. DR. JUAN P. GARRAHAN (997664789) nan participant REC € 0 € 129,420 € 0
Germany HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (999470347) DE114815244 coordinator REC € 0 € 648,992 € 0
Portugal INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES (999813339) PT506134466 participant REC € 0 € 155,100 € 0
United Kingdom UNIVERSITY OF GLASGOW (999974165) GB671798093 participant HES € 0 € 277,992 € 0
Spain UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE (999851363) ESQ5350015C participant HES € 0 € 222,000 € 0
Germany UNIVERSITAET GREIFSWALD (999858056) DE137584813 participant HES € 0 € 256,800 € 0
Switzerland UNIVERSITATSSPITAL BASEL (999898602) CHE115173213MWST participant PUB € 0 € 247,200 € 0